These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9806029)

  • 1. Impact of heterozygosity for the chemokine receptor CCR5 32-bp-deleted allele on plasma virus load and CD4 T lymphocytes in perinatally human immunodeficiency virus-infected children at 8 years of age.
    Buseyne F; Janvier G; Teglas JP; Ivanoff S; Burgard M; Bui E; Mayaux MJ; Blanche S; Rouzioux C; Rivière Y
    J Infect Dis; 1998 Oct; 178(4):1019-23. PubMed ID: 9806029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. French Pediatric HIV Infection Study Group.
    Misrahi M; Teglas JP; N'Go N; Burgard M; Mayaux MJ; Rouzioux C; Delfraissy JF; Blanche S
    JAMA; 1998 Jan; 279(4):277-80. PubMed ID: 9450710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between CCR5 genotype and the clinical course of HIV-1 infection.
    de Roda Husman AM; Koot M; Cornelissen M; Keet IP; Brouwer M; Broersen SM; Bakker M; Roos MT; Prins M; de Wolf F; Coutinho RA; Miedema F; Goudsmit J; Schuitemaker H
    Ann Intern Med; 1997 Nov; 127(10):882-90. PubMed ID: 9382366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors.
    Cohen OJ; Vaccarezza M; Lam GK; Baird BF; Wildt K; Murphy PM; Zimmerman PA; Nutman TB; Fox CH; Hoover S; Adelsberger J; Baseler M; Arthos J; Davey RT; Dewar RL; Metcalf J; Schwartzentruber DJ; Orenstein JM; Buchbinder S; Saah AJ; Detels R; Phair J; Rinaldo C; Margolick JB; Pantaleo G; Fauci AS
    J Clin Invest; 1997 Sep; 100(6):1581-9. PubMed ID: 9294127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia.
    Pasi KJ; Sabin CA; Jenkins PV; Devereux HL; Ononye C; Lee CA
    Br J Haematol; 2000 Oct; 111(1):136-42. PubMed ID: 11091193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects.
    Goh WC; Markee J; Akridge RE; Meldorf M; Musey L; Karchmer T; Krone M; Collier A; Corey L; Emerman M; McElrath MJ
    J Infect Dis; 1999 Mar; 179(3):548-57. PubMed ID: 9952360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of influenza virus vaccine on the expression of human immunodeficiency virus co-receptor CCR5.
    Rucker RP; Day NK; Good RA; Kamchaisatian W; Emmanuel P; Sleasman JW; Mayeski C; Dinglasan E; Haraguchi S; Tangsinmankong N
    Ann Allergy Asthma Immunol; 2004 Sep; 93(3):272-6. PubMed ID: 15478388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between CCR5
    Martínez-Bonet M; González-Serna A; Clemente MI; Morón-López S; Díaz L; Navarro M; Puertas MC; Leal M; Ruiz-Mateos E; Martinez-Picado J; Muñoz-Fernández MA
    Clin Microbiol Infect; 2017 May; 23(5):318-324. PubMed ID: 28042001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32.
    Henrich TJ; Hanhauser E; Hu Z; Stellbrink HJ; Noah C; Martin JN; Deeks SG; Kuritzkes DR; Pereyra F
    AIDS; 2015 May; 29(8):867-76. PubMed ID: 25730507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism in the CCR5 gene promoter and HIV-1 infection in North Indians.
    Kaur G; Singh P; Rapthap CC; Kumar N; Vajpayee M; Sharma SK; Wanchu A; Mehra NK
    Hum Immunol; 2007 May; 68(5):454-61. PubMed ID: 17462514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness.
    Wilkinson DA; Operskalski EA; Busch MP; Mosley JW; Koup RA
    J Infect Dis; 1998 Oct; 178(4):1163-6. PubMed ID: 9806051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MT-2 tropism and CCR-5 genotype strongly influence disease progression in HIV-1-infected individuals.
    Bratt G; Leandersson AC; Albert J; Sandström E; Wahren B
    AIDS; 1998 May; 12(7):729-36. PubMed ID: 9619804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased HIV type 1 transcription in CCR5-Δ32 heterozygotes during suppressive antiretroviral therapy.
    Wang C; Abdel-Mohsen M; Strain MC; Lada SM; Yukl S; Cockerham LR; Pilcher CD; Hecht FM; Sinclair E; Liegler T; Richman DD; Deeks SG; Pillai SK
    J Infect Dis; 2014 Dec; 210(11):1838-43. PubMed ID: 24935955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection.
    de Roda Husman AM; Blaak H; Brouwer M; Schuitemaker H
    J Immunol; 1999 Oct; 163(8):4597-603. PubMed ID: 10510404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of plasma HIV RNA, CD4+ T lymphocytes, and the chemokine receptors CCR5 and CCR2b on HIV disease progression in hemophiliacs. Hemophilia Growth and Development Study.
    Daar ES; Lynn H; Donfield S; Gomperts E; Hilgartner MW; Hoots K; Chernoff D; Winkler C; O'Brien SJ
    J Acquir Immune Defic Syndr; 1999 Aug; 21(4):317-25. PubMed ID: 10428111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex.
    van Rij RP; Portegies P; Hallaby T; Lange JM; Visser J; de Roda Husman AM; van 't Wout AB; Schuitemaker H
    J Infect Dis; 1999 Sep; 180(3):854-7. PubMed ID: 10438379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors.
    Betts MR; Krowka JF; Kepler TB; Davidian M; Christopherson C; Kwok S; Louie L; Eron J; Sheppard H; Frelinger JA
    AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1219-28. PubMed ID: 10480635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of mother-to-infant transmission of HIV-1 is not reduced in CCR5/delta32ccr5 heterozygotes.
    Edelstein RE; Arcuino LA; Hughes JP; Melvin AJ; Mohan KM; King PD; McLellan CL; Murante BL; Kassman BP; Frenkel LM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Dec; 16(4):243-6. PubMed ID: 9402070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCR5 promoter polymorphisms in a Kenyan perinatal human immunodeficiency virus type 1 cohort: association with increased 2-year maternal mortality.
    John GC; Bird T; Overbaugh J; Nduati R; Mbori-Ngacha D; Rostron T; Dong T; Kostrikis L; Richardson B; Rowland-Jones SL
    J Infect Dis; 2001 Jul; 184(1):89-92. PubMed ID: 11398114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of highly active antiretroviral treatment on expression of HIV-1 coreceptors and ligand levels in peripheral blood from HIV-1 infected patients in China.
    Fang J; Bai S; Wu L; Zhu X; Yao X; Jin C; Wang C
    J Int Med Res; 2013 Oct; 41(5):1560-9. PubMed ID: 24043708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.